VRDN vs. PMD, FTRE, VCYT, CDNA, CSTL, FLGT, CELC, SERA, BDSX, and BNR
Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include Psychemedics (PMD), Fortrea (FTRE), Veracyte (VCYT), CareDx (CDNA), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Celcuity (CELC), Sera Prognostics (SERA), Biodesix (BDSX), and Burning Rock Biotech (BNR). These companies are all part of the "medical laboratories" industry.
Psychemedics (NASDAQ:PMD) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.
In the previous week, Psychemedics had 1 more articles in the media than Viridian Therapeutics. MarketBeat recorded 3 mentions for Psychemedics and 2 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.43 beat Psychemedics' score of 1.02 indicating that Psychemedics is being referred to more favorably in the media.
Psychemedics has higher revenue and earnings than Viridian Therapeutics. Psychemedics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.
32.1% of Psychemedics shares are held by institutional investors. 24.0% of Psychemedics shares are held by insiders. Comparatively, 0.7% of Viridian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Psychemedics received 93 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. Likewise, 74.35% of users gave Psychemedics an outperform vote while only 72.06% of users gave Viridian Therapeutics an outperform vote.
Viridian Therapeutics has a consensus price target of $34.60, indicating a potential upside of 189.54%. Given Psychemedics' higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than Psychemedics.
Psychemedics has a net margin of -20.23% compared to Psychemedics' net margin of -75,737.85%. Viridian Therapeutics' return on equity of -59.21% beat Psychemedics' return on equity.
Psychemedics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.
Summary
Psychemedics beats Viridian Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Viridian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viridian Therapeutics Competitors List
Related Companies and Tools
